Latest Insider Transactions at Xilio Therapeutics, Inc. (XLO)
This section provides a real-time view of insider transactions for Xilio Therapeutics, Inc. (XLO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Xilio Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Xilio Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
1,803
-36.06%
|
$0
$0.98 P/Share
|
|
Jan 02
2025
|
Christopher James Frankenfield Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,954
-35.89%
|
$0
$0.98 P/Share
|
|
Jan 01
2025
|
Rene Russo PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,250
+15.3%
|
-
|
|
Jan 01
2025
|
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 01
2025
|
Christopher James Frankenfield Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,375
+50.0%
|
-
|
|
Jan 01
2025
|
Katarina Luptakova CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,625
+50.0%
|
-
|
|
Dec 18
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,759,978
+16.2%
|
$1,759,978
$1.04 P/Share
|
|
Apr 02
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
485,250
+6.2%
|
$0
$0.76 P/Share
|
|
Feb 08
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
267
-0.04%
|
$0
$0.64 P/Share
|
|
Feb 08
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
733
-0.04%
|
$0
$0.64 P/Share
|
|
Jan 12
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
560
-0.08%
|
$0
$0.83 P/Share
|
|
Jan 12
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,540
-0.08%
|
$0
$0.83 P/Share
|
|
Jan 11
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
569
-0.08%
|
$0
$0.87 P/Share
|
|
Jan 11
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,566
-0.08%
|
$0
$0.87 P/Share
|
|
Dec 10
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.44%
|
$225,000
$9.9 P/Share
|
|
Dec 09
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,011
+0.14%
|
$36,099
$9.84 P/Share
|
|
Dec 08
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
13,458
+0.48%
|
$121,122
$9.62 P/Share
|
|
Oct 26
2021
|
Sv7 Impact Medicine Fund LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,301,132
+34.43%
|
-
|
|
Oct 26
2021
|
Sv7 Impact Medicine Fund LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,301,132
+34.43%
|
-
|
|
Oct 26
2021
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
1,881,355
+36.48%
|
-
|
|
Oct 26
2021
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
775,000
+25.3%
|
$12,400,000
$16.0 P/Share
|
|
Oct 26
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,512,944
+50.0%
|
-
|
|
Oct 26
2021
|
Fil LTD |
BUY
Conversion of derivative security
|
Indirect |
218,705
+50.0%
|
-
|
|
Oct 26
2021
|
Alexandria Venture Investments, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
166,423
+50.0%
|
-
|
|
Oct 26
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
187,500
+20.3%
|
$3,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,545,529
+41.03%
|
-
|
|
Oct 26
2021
|
Bay City Capital LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
312,500
+21.67%
|
$5,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
Bay City Capital LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
816,990
+32.81%
|
-
|
|
Oct 26
2021
|
K Ga A Merck > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
680,825
+39.0%
|
-
|
|
Oct 26
2021
|
River Vest Venture Fund Iv, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+14.78%
|
$4,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
River Vest Venture Fund Iv, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,191,444
+36.59%
|
-
|
|
Oct 26
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,475,121
+50.0%
|
-
|
|
Oct 26
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+28.47%
|
$8,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
907,766
+50.0%
|
-
|